Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0327 • ACR Convergence 2022
SMART-SLE: Serology Monitoring and Repeat Testing in Systemic Lupus Erythematosus
Ai Li Yeo¹, Rangi Kandane-Rathnayake², Rachel Koelmeyer³, Vera Golder², Worawit Louthrenoo⁴, Yi-Hsin Chen⁵, Jiacai Cho⁶, Aisha Lateef⁷, Laniyati Hamijoyo⁸, Luo Shue Fen⁹, Yeong-Jian Wu⁹, Sandra Navarra¹⁰, Leonid Zamora¹¹, Zhanguo Li¹², An Yuan¹³, Sargunan Sockalingam¹⁴, Yasuhiro Katsumata¹⁵, Masayoshi Harigai¹⁵, Yanjie Hao¹⁶, Zhouli Zhang¹⁷, Duminda Basnayake¹⁸, Madelynn Chan¹⁹, Jun Kikuchi²⁰, Tsutomu Takeuchi²¹, Sang-Cheol Bae²², Shereen Oon²³, Sean O'Neill²⁴, Fiona Goldblatt²⁵, Kathy Gibson²⁴, Kristine Ng²⁶, Hui Nee Annie Law²⁷, Nicole Tugnet²⁸, Sunil Kumar²⁹, Cherica Tee³⁰, Michael Tee³⁰, Yoshiya Tanaka³¹, Naoaki Ohkubo³¹, Chak Sing³², Mandana Nikpour³³, Alberta Hoi³⁴, Michelle Leech³ and Eric Morand³⁵, ¹Monash Health and Monash University, Melbourne, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia, ⁴Chiang Mai University, Chiang Mai, Thailand, ⁵Taichung Veterans General Hospital, Taichung, Taiwan, ⁶National University Health System (NUHS), Singapore, Singapore, ⁷National University Hospital, Singapore, Singapore, ⁸Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁹Chang Gung Memorial Hospital, Taoyuan, Taiwan, ¹⁰University of Santo Tomas, Manila, Philippines, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Beijing, China, ¹³Peking University Health Science Center, Beijing, China, ¹⁴University of Malaya, Kuala Lumpur, Malaysia, ¹⁵Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹⁶The University of Melbourne, Melbourne, Australia, ¹⁷Peking University First Hospital, Beijing, China, ¹⁸Teaching Hospital Kandy, Kandy, Sri Lanka, ¹⁹Tan Tock Seng Hospital, Singapore, Singapore, ²⁰Keio University, Tokyo, Japan, ²¹Keio University and Saitama Medical University, Tokyo, Japan, ²²Hanyang University Medical Center, Seoul, Republic of Korea, ²³St Vincent's Hospital, Fitzroy, Australia, ²⁴Liverpool Hospital, Sydney, Australia, ²⁵Flinders Medical Centre, Adelaide, Australia, ²⁶North Shore Hospital, Auckland, New Zealand, ²⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁸Greenlane Clinical Centre, Auckland, New Zealand, ²⁹Middlemore Hospital, Auckland, New Zealand, ³⁰University of the Philippines, Quezon City, Philippines, ³¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³²The University of Hong Kong, Pok Fu Lam, Hong Kong, ³³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³⁴Monash Health, Melbourne, Australia, ³⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Disease monitoring in systemic lupus erythematosus (SLE) includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive, the…
Abstract Number: 0345 • ACR Convergence 2022
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
Alba Herrero-Morant¹, Jon Zubiaur-Zamacola², Adrián Margarida-De Castro², Raquel Pérez-Barquín², Miguel Ángel González-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE). It may cause cardiac alterations which includes short term arrhythmic events (via…
Abstract Number: 0367 • ACR Convergence 2022
Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
April Jorge¹, Baijun Zhou¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Patients with SLE are at increased risk of COVID-19 and its severe outcomes, in part due to the use of immunosuppressants. We sought to…
Abstract Number: 0632 • ACR Convergence 2022
Single-cell Multiomic Profiling Differentiates Ancestral B Cell Pathologies Contributing to Lupus Disease Activity
Kevin Thomas, Miles Smith, Samantha Slight-Webb, Susan Macwana, Joseph Kheir, Carla J. Guthridge, Wade deJager, Christian Wright, Bolanle Adebayo, Judith James and Joel Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Genetic ancestry impacts SLE prevalence, clinical presentation, and treatment response; however, the molecular underpinnings of this disparity remain poorly understood. Recent findings demonstrate that…
Abstract Number: 0652 • ACR Convergence 2022
Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway
Shohei Nakamura, Yuko okamoto, Yasuhiro Katsumata and Masayoshi Harigai, Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Background/Purpose: Although type 1 interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM) [1] as typically evidenced…
Abstract Number: 0670 • ACR Convergence 2022
A Short Allelic Epitope Coded by HLA-DRB1*03:01 Activates a Systemic Lupus Erythematosus Cell Aberration Cascade
Bruna Miglioranza Scavuzzi¹, Bhavneet Kaur¹, Vincent Van Drongelen¹, Raquel Mesquita-Ferrari², Amr Sawalha³, Frederick Miller⁴ and Joseph Holoshitz¹, ¹University of Michigan, Ann Arbor, MI, ²Universidade Nove de Julho (UNINOVE), São Paulo, Brazil, ³University of Pittsburgh, Pittsburgh, PA, ⁴Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease resulting from an interaction of genetic, epigenetic, hormonal, environmental and immunoregulatory influences. It has been well…
Abstract Number: 0956 • ACR Convergence 2022
Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers
Nicola Fraser¹, Mala Masson², Kristina Deonaraine³, Philip Carlucci⁴, Colin Phoon⁵, Ashley Roman⁵, Peter Izmirly⁶, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield⁵, Young Mi Lee⁵, Julie Nusbaum⁷, Bruce Solitar⁵, Fardina Malik⁵, Paula Rackoff¹, Rebecca Haberman¹, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Albuhamad⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Nelangi Pinto¹², Anita Moon-Grady¹³, Lisa Howley¹⁴, Stephanie Levasseur¹⁵, Jyothi Matta¹⁶, Christopher Lindblade¹⁷, Andrew Rubenstein¹⁸, Caitlin Haxel¹⁹, Katherine Kohari²⁰, Joshua Copel²⁰, James Strainic²¹, Tam Doan²², Karla Bermudez-Wagner²², Shreya Sunil Sheth²², Stacy Killen²³, Theresa Tacy²⁴, Michelle Kaplinski²⁴, Bailey Drewes²⁵, Robert Clancy⁶, Bettina Cuneo²⁶ and Jill Buyon⁶, ¹NYU School of Medicine, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³University at Buffalo, Buffalo, NY, ⁴NYU Langone, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Long Island School of Medicine, Mineola, NY, ⁸Children's Heart Center, Las Vegas, ⁹East Virginia Medical School, Norfolk, VA, ¹⁰University of Kentucky, Lexington, KY, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, ¹³UCSF, San Francisco, ¹⁴Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁵Columbia University, New York, NY, ¹⁶University of Louisville, Louisville, KY, ¹⁷Phoenix Children's Hospital, Phoenix, ¹⁸Dignity Health, Phoenix, ¹⁹University of Vermont Children's Hospital, Burlington, VT, ²⁰Yale University, New Haven, CT, ²¹UH Rainbow Babies, Cleveland, OH, ²²Baylor College of Medicine, Houston, TX, ²³Vanderbilt University, Nashville, TN, ²⁴Stanford University, Stanford, CA, ²⁵University of Colorado, Denver, CO, ²⁶University of Colorado School of Medicine, Aurora, CO
Background/Purpose: While it is well accepted that congenital heart block (CHB) and neonatal annular rash are highly associated with maternal anti-Ro60 and 52 autoantibodies, the…
Abstract Number: 0977 • ACR Convergence 2022
Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
Jason S Knight¹, Winn Walter Chatham², Christine Henning³, Julia H N Harris⁴, Andre Van Maurik⁵, Roger A Levy⁶ and David Pisetsky⁷, ¹University of Michigan, Division of Rheumatology, Ann Arbor, MI, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL, ³GlaxoSmithKline, Global Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷Duke University Medical Center, Durham, NC
Background/Purpose: Serological and cellular biomarkers are used in clinical practice to guide the management of SLE. Increased levels of anti-dsDNA and decreased levels of complement…
Abstract Number: 0994 • ACR Convergence 2022
Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus
Michelle Petri¹, Daniel Joyce², Kristin Haag², Andrea Fava³, Daniel W. Goldman¹, Diana Zhong², Shaoming Xiao⁴, Aaron M. Milstone² and Laurence S Magder⁵, ¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD
Background/Purpose: The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE), and immunosuppressive medications including corticosteroids impact the risk. Furthermore, immunosuppressive…
Abstract Number: 1133 • ACR Convergence 2022
Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus
Cecilia Chung, Gul Karakoc, Jorge Gamboa, Jonathan Mosley, Nancy Cox, Michael Stein and Vivian Kawai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem condition that occurs more frequently in certain racial groups, particularly in populations of African ancestry. Low white…
Abstract Number: 1305 • ACR Convergence 2022
Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus
Joshua Novack¹, Gregory Chang², Stephen Honig¹, Anmol Monga², Xiaoliu Zhang³, Punam Saha³, Dimitri Martel², Peter Izmirly⁴, H Michael Belmont⁵, Jill Buyon⁴ and Amit Saxena⁵, ¹NYU Langone Health Department of Medicine, New York, NY, ²NYU Langone Health Department of Radiology, New York, NY, ³University of Iowa Departments of Radiology and Electrical and Computer Engineering, Iowa City, IA, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY
Background/Purpose: Fractures in patients with systemic lupus erythematosus (SLE) are more common than age and sex matched controls. Fracture risk is traditionally assessed by dual-energy…
Abstract Number: 1384 • ACR Convergence 2022
Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus
Amanda Marsden¹, Georgina Tiller², Angelyne Rivera³, Maitri Deep Rai³, Lori Tucker³, Jaime Guzman⁴, Kimberly Morishita², Kristin Houghton², Shreya Moodley³ and David Cabral⁵, ¹BC Children's Hospital, Castle Hill, Australia, ²University of British Columbia - Vancouver, Vancouver, BC, Canada, ³British Columbia Children's Hospital, Vancouver, BC, Canada, ⁴University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, ⁵BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Childhood onset SLE is an autoantibody mediated, multisystem disease which can include cardiac manifestations. Because cardiac involvement can develop insidiously, an earlier review from…
Abstract Number: 1456 • ACR Convergence 2022
Latin-American Systemic Lupus Erythematosus Clusters
Rosana Quintana¹, Romina Nieto², Marina Scolnik³, Nidia Meras⁴, Cintia Otaduy⁵, María Emilia Sattler⁶, Luciana González Lucero⁷, Nicolas Perez⁸, Ana Silva⁹, Odirlei Monticielo¹⁰, Angela Luzia B Duarte¹¹, Edgard Reis Neto¹², Milena Mimica¹³, Gustavo Aroca Martinez¹⁴, Gerardo Quintana-Lopez¹⁵, Mario Moreno Alvarez¹⁶, Miguel Angel Saavedra Salinas¹⁷, Margarita Portela¹⁸, Luis H Silveira¹⁹, Ignacio García Valladares²⁰, Carlos Abud-Mendoza²¹, Jorge Esquivel-Valerio²², Maria Duarte²³, Roberto Muñoz Louis²⁴, Vicente Juárez²⁵, Eduardo Ferreira Borba Neto²⁶, Luis Catoggio²⁷, Graciela Alarcón²⁸, Jose Puerta²⁹, Guillermina Harvey³⁰, Elisa Novati³¹, Valeria Arturi³², Wilfredo Grageda³³, Cecilia Pisoni³⁴, Francinne Machado Riobeiro³⁵, Emily Figueiredo Neves Yuki²⁶, Iris Guerra Herrera³⁶, Gabriel Tobón³⁷, Andres Cadena Bonfanti¹⁴, Hilda Fragoso-Loyo³⁸, Marie Teresa de Martinez³⁹, Claudia Selene Mora Trujillo⁴⁰, Manuel Ugarte-Gil⁴¹, Ernesto Zavala Flores⁴², Ricardo Robaina⁴³, Gonzalo Silveira⁴⁴, Federico Zazzetti⁴⁵, Ashley Orillion⁴⁶, Guillermo Pons-Estel⁴⁷, Bernardo Pons-Estel² and Urbano Sbarigia⁴⁸, ¹Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ²Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Cordoba, Argentina, ⁵Hospital Córdoba, Córdoba, Argentina, ⁶Sanatorio Británico, Paraná, Argentina, ⁷Hospital Padilla, San Miguel de Tucumán, Argentina, ⁸Instituto Lanari, Buenos Aires, Argentina, ⁹Hospital das Clinicas, Univerisad Federal de Goias, Goiania, Brazil, ¹⁰Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹¹Universidade Federal de Pernambuco, Recife, Brazil, ¹²Universidad Federal São Paulo, São Paulo, Brazil, ¹³Universidad San Sebastián, Santiago, Chile, ¹⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ¹⁵Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital. Bogota, Colombia; Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia. Bogota, Colombia; Department of Internal Medicine. School of Medicine, Universidad de Los Andes, Bogotá, Colombia, ¹⁶Hospital Luis Vernaza, Guayaquil, Ecuador, ¹⁷IMSS, Ciudad de México, Mexico, ¹⁸Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ¹⁹Instituto Nacional de Cardiología, Ciudad de México, Mexico, ²⁰CEIBAC, SC, Guadalajara, Mexico, ²¹Hospital Central and Faculty of Medicine, UASLP, San Luis Potosí, Mexico, ²²Hospital Universitario “Dr. José Eleuterio Gonzalez", Monterrey, Mexico, ²³Hospital de Clínicas Paraguay, Asunción, Paraguay, ²⁴Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ²⁵MSP, Salta, Argentina, ²⁶Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²⁷Hospital Italiano de Buenos Aires, Olivos, Argentina, ²⁸The University of Alabama at Birmingham, Oakland, ²⁹Rheumatology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain, ³⁰Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Santa Fe, Argentina, ³¹Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³²Hospital HIGA San Martín, Buenos Aires, Argentina, ³³Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ³⁴CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ³⁵Hospital Universitario Pedro Ernesto, UERJ, Rio de Janiero, Brazil, ³⁶Hospital del Salvador, Santiago, Chile, ³⁷Fundación Valle del Lili, Calí, Colombia, ³⁸Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³⁹Hospital de Clínicas I, Montevideo, Uruguay, ⁴⁰Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴¹Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁴²Hospital Cayetano Heredia, San Martín de Porres Distric, Peru, ⁴³Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁴Grupo de Investigacion de EAIS y Reumatológicas, A Coruña, Spain, ⁴⁵Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁴⁶Janssen, Horsham, PA, ⁴⁷CREAR, Rosario, Argentina, ⁴⁸Johnson & Johnson, Beerse, Belgium
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. The identification of patient subgroups or clusters may be useful for the management…
Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Rosa Arvizu-Rivera¹, jiram torres-Ruiz², Alfredo Pérez-Fragoso², Beatriz Alcalá-Carmona³, Miroslava Nuñez-Aguirre⁴, Ana Sofía Vargas-Castro⁴, Abdiel Absalón-Aguilar³, Jaquelin Lira-Luna⁴ and Diana Gómez-Martín², ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ²INCMNSZ, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…
Abstract Number: 1631 • ACR Convergence 2022
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Ken Yasaka¹, Tomohide Yamazaki², Hiroko Sato¹, Tsuyoshi Shirai¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae⁴, ¹Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ²SBI Biotech, Tokyo, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ⁴Department of Hematology, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].